Vycor Medical to Present at the LD Micro 4th Invitational Conference
29 Maggio 2014 - 4:21PM
Marketwired
Vycor Medical to Present at the LD Micro 4th Invitational
Conference
Company to Present at 9:30 a.m. June 4, 2014
BOCA RATON, FL--(Marketwired - May 29, 2014) - Vycor Medical,
Inc. ("Vycor") (OTCQB: VYCO), a provider of innovative and superior
surgical and therapeutic solutions, today announced that David
Cantor, President, and Peter C. Zachariou, Chief Executive Officer,
will present at the LD Micro 4th Invitational Conference. The
Company's presentation is scheduled for 9:30 a.m. (PT) June 4, 2014
in track two.
The conference is being held at the Luxe Hotel, 11461 Sunset
Boulevard, Los Angeles, CA. Mr. Cantor and Mr. Zachariou will be
available during the day on June 4, 2014 for one-on-one meetings.
To schedule a one-on-one meeting, please contact your LD Micro
representative.
The Company's group presentation will be available for the
public to access at http://wsw.com/webcast/ldmicro6/vyco or via its
corporate website at www.vycormedical.com.
About LD MICRO:
LD MICRO is a by-invitation only newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published an annual list of recommended stocks as well
as comprehensive reports on select companies throughout the year.
LD MICRO concentrates on finding, researching, and investing in
companies that are overlooked by institutional investors. It is a
non-registered investment advisor. To register, please contact
Chris Lahiji at (408) 457-1042 or chris@ldmicro.com.
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical,
Inc. ("Vycor") is a publicly traded company (OTCQB: VYCO) dedicated
to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of
FDA cleared medical solutions that are changing and improving lives
every day. The Company operates two business units: Vycor Medical
and NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating
revenue.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. The company is ISO 13485:2003
compliant, has U.S. FDA 510(k) clearance for brain and spine
surgeries and full regulatory approvals for brain in Australia,
Canada, China, Europe (EU - Class III), and Japan and is seeking or
has partial regulatory approvals in India, Korea, Russia, Taiwan,
Brazil and Vietnam. For an overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy®
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also
has CE Marking for the EU. NovaVision also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect.
In March 2014 the Company launched NeuroEyeCoach™ which is the
first commercially available saccadic therapy deliverable via the
web to patients's computer at their own home. The program is
supported by more than four decades of scientific findings and was
developed as collaboration between the Company, and Josef Zihl, a
NovaVision Scientific Advisor and world thought leader in saccadic
training and the pioneer of this computer based training technique.
The program is designed to result in a meaningful improvement in
the patients visual search performance resulting in improvements in
their navigation and object finding skills. Given that
NeuroEyeCoach™ addresses the patients difficulty with their eye
movements and their ability to integrate visual information while
VRT focuses on the restoration of lost vision the two therapies are
highly complementary. For an overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Grafico Azioni Vycor Medical (QB) (USOTC:VYCO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Vycor Medical (QB) (USOTC:VYCO)
Storico
Da Giu 2023 a Giu 2024
